Table 3 Immune responses to pneumococcal polysaccharides at one month post-primary vaccination (primary ATP immunogenicity cohort): OPA
| Â | Clin group | Com group | ||||
|---|---|---|---|---|---|---|
|  | N | % ≥8 | GMT | N | % ≥8 | GMT |
(95% CI) | (95% CI) | (95% CI) | (95% CI) | |||
Vaccine serotypes | Â | Â | Â | Â | Â | Â |
Serotype 1 | 209 | 88.5 | 128.9 | 210 | 90.0 | 122.1 |
(83.4 – 92.5) | (102.7 – 161.7) | (85.1 – 93.7) | (98.3 – 151.7) | |||
Serotype 4 | 207 | 100 | 698.3 | 207 | 98.1 | 609.3 |
(98.2 – 100) | (619.6 – 786.9) | (95.1 – 99.5) | (519.6 – 714.3) | |||
Serotype 5 | 207 | 98.6 | 127.9 | 210 | 96.7 | 98.6 |
(95.8 – 99.7) | (109.0 – 149.9) | (93.3 – 98.6) | (83.0 – 117.1) | |||
Serotype 6B | 205 | 95.6 | 870.7 | 206 | 92.7 | 619.2 |
(91.8 – 98.0) | (710.2 – 1067.6) | (88.3 – 95.9) | (483.4 – 793.2) | |||
Serotype 7F | 206 | 100 | 3905.8 | 208 | 100 | 3585.7 |
(98.2 – 100) | (3420.2 – 4460.4) | (98.2 – 100) | (3119.8 – 4121.2) | |||
Serotype 9V | 207 | 100 | 1800.0 | 208 | 100 | 1851.3 |
(98.2 – 100) | (1596.6 – 2029.3) | (98.2 – 100) | (1612.3 – 2125.8) | |||
Serotype 14 | 209 | 99.5 | 1521.0 | 208 | 99.5 | 1485.8 |
(97.4 – 100) | (1313.3 – 1761.6) | (97.4 – 100) | (1280.5 – 1724.0) | |||
Serotype 18C | 204 | 99.0 | 533.5 | 206 | 96.6 | 383.9 |
(96.5 – 99.9) | (461.8 – 616.4) | (93.1 – 98.6) | (319.3 – 461.5) | |||
Serotype 19F | 206 | 98.1 | 689.6 | 206 | 97.1 | 573.5 |
(95.1 – 99.5) | (581.1 – 818.2) | (93.8 – 98.9) | (477.2 – 689.3) | |||
Serotype 23F | 209 | 99.0 | 2716.7 | 207 | 99.5 | 2379.5 |
(96.6 – 99.9) | (2316.3 – 3186.3) | (97.3 – 100) | (2043.4 – 2770.7) | |||
Cross-reacting serotypes | Â | Â | Â | Â | Â | Â |
Serotype 6A | 197 | 87.8 | 230.8 | 200 | 85.5 | 173.7 |
(82.4 – 92.0) | (180.3 – 295.4) | (79.8 – 90.1) | (133.9 – 225.3) | |||
Serotype 19A | 197 | 42.1 | 18.1 | 199 | 37.7 | 15.1 |
(35.1 – 49.4) | (13.7 – 23.8) | (30.9 – 44.8) | (11.5 – 19.8) | |||